The link between alcohol consumption and liver disease is not direct and several factors including autoimmunity to hepatocyte components have been implicated. We have previously identified alcohol dehydrogenase (ADH) as an autoantigen in autoimmune liver disease and in a proportion of patients with alcoholic liver disease. The aim of the present study is to investigate the association between the presence of anti-ADH antibodies, alcohol consumption and severity of liver damage in alcoholic patients. The presence of antibodies to human ADH 132 and horse ADH was investigated in 108 patients with documented history of alcohol consumption and alcohol related liver disease, 86 being active alcohol abusers and 22 on sustained alcohol withdrawal, 39 with non-alcohol related disease and 22 normal subjects.
The link between alcohol consumption and liver disease is not direct and several factors including autoimmunity to hepatocyte components have been implicated. We have previously identified alcohol dehydrogenase (ADH) as an autoantigen in autoimmune liver disease and in a proportion of patients with alcoholic liver disease. The aim of the present study is to investigate the association between the presence of anti-ADH antibodies, alcohol consumption and severity of liver damage in alcoholic patients. The presence of antibodies to human ADH 132 and horse ADH was investigated in 108 patients with documented history of alcohol consumption and alcohol related liver disease, 86 being active alcohol abusers and 22 on sustained alcohol withdrawal, 39 with non-alcohol related disease and 22 normal subjects.
Antibodies to either ADH form were more frequently detected in active alcohol abusers (55/86, 64%) than in patients on sustained alcohol withdrawal longer than 6 months (118, 13 %, P<0.005), HBV infection (2/8,25%, P=0.03), non-alcohol related disease (9/29 , 23%, P<O.OOOl) and in normal controls (3/22 , 14%, P<O.OOOl)j were more frequent in patients with cirrhosis than in those with steatosis (26/34,76% vs 34/64, 53%, P=0.02)j and were associated with elevated levels of ALT (anti-ADH 132, P<0.05), immunoglobulin A (P<0.05) and v-glutamyl transpeptidase (P=O.Ol). Anti-ADH antibody positive serum samples were able to inhibit the enzymatic activity of ADH. These findings suggest that anti-ADH antibodies may be triggered by alcohol consumption and act as a disease activity marker in alcoholic liver disease.
Excessive alcohol intake is associated with acute and chronic liver damage including steatosis, alcoholic hepatitis and cirrhosis (1) (2) . The connection between alcohol consumption and liver damage is not direct, however, since heavy drinking is not necessarily associated with hepatocyte damage and only one in six people who drink heavily develop cirrhosis (1) . A number of contributory factors have been invoked to explain the link between excessive alcohol intake and liver disease (3) (4) , including genetic predisposition (5) and the triggering of an autoimmune attack on the hepatocyte (6) .
Non-organ and liver specific autoantibodies have been described in patients with alcoholic liver disease (ALD), such as anti-liver specific lipoprotein (LSP) antibodies and their prevalence is associated with disease activity (7) (8) (9) (10) . Anti-LSP is more common in patients with active cirrhosis (60%) than in those with inactive cirrhosis or fatty changes (15%), An immunoregulatory defect was also shown in patients actively abusing alcohol but not when they stopped drinking (11) . Alcohol per se may therefore induce alterations in the immune system predisposing to autoimmunity (7, 12) .
We have previously reported that human alcohol dehydrogenase (ADH) is a component ofLSP and an autoantibody target in patients with autoimmune hepatitis (13) . In the same study we noted that anti-ADH antibodies were present, at a prevalence similar to that seen in autoimmune liver disease (50%), in a small control group of patients with ALD and that observation triggered the present study (13) .
Ethanol is metabolised mainly by the polymorphic liver ADH enzyme, the isoforms of which are variably composed of a (encoded by geneADHl), 131, 132, 133 (ADH2), )'1,)'2 (ADH3) subunits sharing about 95% identity and closely related to each other in terms of their enzymatic activity, amino acid composition and immunological characteristics (14) (15) .
In the present study we have studied the presence of anti-ADH antibodies in a large series of patients both abusing alcohol and on alcohol withdrawal with documented liver disease and in patients without alcohol related liver or non-liver disease. We have investigated anti-ADH antibodies direct against human ADH 132, which is a recombinant protein purified through sequential chromatography, and horse ADH, which is highly homologous to human ADH and commercially available, and their dynamic changes during alcohol withdrawal. We also investigated whether anti-ADH antibody affects the catalytic activity of this enzyme.
MA TERIALS AND METHODS

Patients and controls
One hundred and eight Italian patients with alcoholic liver disease were studied (95 males, median age 50 years, range 22 -80). All patients were attending an out-patient clinic at the Department of Internal Medicine, University of Milan, Italy. The severity of cirrhosis was defined according to the Child criteria. The diagnosis and severity of alcoholic liver disease was based on a history of excessive alcohol consumption, clinical features ofliverdisease, biochemical findings, ultrasonography, esophagogastroscopy and liver biopsy (16) . History of alcohol consumption was obtained through an interview and a Munchner Alcoholismusest questionnaire (17) . Eighty-six patients were active alcohol abusers (AAA) defined on the basis of an alcohol intake exceeding 60 g/day in males and 40 g/day in females for more than five years (18) . Nine of them were followed from the time of active alcohol abuse to that of alcohol withdrawal for a median of 40 days into abstinence (range 30 to 100 days). Twenty-two ofthe 108 patients were on sustained alcohol withdrawal (SAW), having abstained from alcohol intake 3 months (14 patients, SAW group A) to longer than 6 months (up to 3 years, 8 patients, SAW group B). As non-alcoholic controls, 39 hospital inpatients (25 males, median age 50 years, range 21 -82) with non-alcohol related diseases were tested. They were in hospital for any reason other than surgery, anaemia, heart failure or diabetes. They had no history of alcohol intake. Twenty blood donors and two healthy laboratory workers (all male, median age 34 years, range 21 -60) were studied as normal controls. The demographic and clinical data of patients and controls are presented in Table I . Aspartate aminotransferase (AST) and alanine transaminase (ALT) levels (upper normal limit: 45 lUll), were assessed in all patients; gglutamyl transpeptidase ()'GT) levels (upper normal limit: 28 lUll) and two markers of alcohol consumption: carbohydrate-deficient transferrin (CDT) (upper normal limit: 20 U/I for man and 26 U/I for woman) and mean corpuscular volume (MCV, upper normal limit: 90fl) were assessed in 106 ALD patients and in all pathological control patients. CDT levels were determined with a radioimmunoassay (CD-TectTM, Kabi Pharmacia). Immunoglobulin A (IgA) levels (normal value <4.0 g/ 1) were measured in 89 ALD patients using a Behring Nephelometric Analyzer II and nephelometric grade specific antisera (Behring Diagnostics Inc., San Jose, CA, USA). Patients were also divided into groups based on whether they had steatosis, hepatitis or cirrhosis (Table II) . This study was approved by the local Ethical Committee.
Presence of HBsAg, anti-HBs, HBeAg, anti-HBe and antibodies to hepatitis B core antigen was tested by commercial enzyme-immunoassays (Abbott Laboratories, North Chicago, IL, USA). Antibodies to hepatitis C virus were detected by ELISA II (Ortho Diagnostics System, Raritan, NJ, USA) and confirmed by RIBA II (Ortho Diagnostics System and Chiron Corp, Emeryville, CA, USA) according to the instructions of the manufacturer.
Detection of Non-organ specific autoantibodies
Anti-nuclear (ANA), anti-mitochondrial (AMA), anti-smooth muscle (SMA) antibodies and liver kidney microsomal antibody type 1 (LKM 1) were investigated by indirect immunofluorescence on 5-mm cryostat sections of rat liver, kidney and stomach (19) at the initial dilution of 1II 0 in phosphate buffer saline (PBS). Positive sera were double-diluted to extinction.
Preparation of human ADH 132
The preparation of recombinant human ADH 132 isoform has been described in detail elsewhere (20) (21) . In brief, the cDNAs of ADH 132 was obtained from a human liver cDNA library using appropriate synthetic nucleotide probe and was ligated into plasmid pKK223-3. The ligation mixtures were then transformed into E.coli JM 105. Purified recombinant ADH 132 was obtained from the lysate supernatant by sequential chromatography.
Detection of anti-ADH antibodies by immunoblot
Antibodies to human ADH 132 subunit and horse liver ADH (17233, Sigma Aldrich, Poole, UK) were detected by immunoblot (13) . In brief, ADH preparations were subjected to electrophoresis in 12% polyacrylamide mini gels (Bio-Rad Laboratories, Heme! Hempstead, UK) and then tran~ferred onto nitrocellulose filters. Non-specific binding was blocked with 1% gelatin. Filter strips were incubated with patients' sera at an initial dilution of 11300, and polypeptides targeted by anti-ADH antibodies were initially visualised using peroxidase-conjugated rabbit anti-human IgA, G and M (DAKO, Copenhagen, Denmark) and thereafter using anti-human IgG (Dako) at a dilution of 1/750 for I hat room temperature. Positive sera were diluted further at 1/600, 111000, 112000 and 113000.
Measurement and inhibition ofhorse ADHenzymatic activity
Enzyme activity of ADH was measured by the production of NADH during incubation of ethanol (33 mM) and NAD+ (2.4 mM) in glycine buffer (0.8ml, 100mM, pH 10) for 200 minutes, with or without the presence of serum (5~) from subjects either anti-ADH antibody positive or negative, or ADH alone. NADH concentration was calculated using an extinction coefficient of 6250M-l cm-1 at 340nm, measured using an Agilent 8453 diode array spectrophotometer (Agilent, UK) (22) .
Statistical analysis
Anti-ADH antibody prevalence in the different groups was compared using the X 2 test. The normality ofvariable distributions was tested using the Kolmogorov-Smirnov goodness of fit test and found that they were not normally distributed. Therefore, differences in levels of AST, ALT, CDT, MCV, 'YGT and IgA between groups were analyzed by Wilcoxon's rank sum test. P values of <0.05 are considered significant.
RESULTS
Prevalence ofanti-ADH antibodies in patients with ALD and its association with severity ofliver disease
Amongst undivided ALD patients, antibodies to human ADH 132 and horse ADH were present in 58 (54%) and48 (44%) of the patients respectively; the prevalence of antibodies to either ADH was 61 % (66/108) ( Table 11 ). Reactivities to human ADH 132 and horse ADH were closely related (X 2 value=35, P<O.OOOl). Fig. I shows the presence of antibodies to human ADH 132 in the sera of representative patients with ALD and in one normal subject. Anti-human ADH 132 antibodies were detected more frequently in patients with cirrhosis (65%) than in those with steatosis (44%, P<0.05). The highest prevalence of anti-ADH 132 was seen in patients with alcoholic hepatitis (75%) (Table   II) .
Associations between anti-ADH antibodies and biochemical markers ofalcoholic liver disease
The associations between anti-ADH antibodies and biochemical markers of alcoholic liver disease are summarized in Table III . Prevalence of antibodies to ADH 132, horse ADH or either ADH was higher in patients with elevated ')'GT levels than in those with normal levels (P=0.003, P<0.05 and P=O.O I for anti-ADH 132, -horse ADH and -either-ADH antibody respectively). Similarly, the prevalence of anti-ADH 132 was higher in patients with elevated ALT (77%) than in those with normal ALT levels (48%, P<0.05) and the prevalence of antibodies to ADH 132 was higher in patients with elevated IgA levels (P=O.O 16 for anti-ADH 132 and P<0.05 for anti either ADH). Conversely, patients positive for anti-ADH 132 had higher IgA levels (median 4.16 gil) than those negative (median 2.89 gil, P=0.006). Frequency of anti-ADH antibodies tended to be higher in patients with elevated CDT and MCV levels (Table III) .
Association between anti-ADH antibodies and alcohol consumption
Associations between anti-ADHs antibodies and drinking patterns are given in Table IV .
Antibodies to human ADH 132 were present in 56% AAA patients, the frequency being higher than in SAW group B (13%, P=O.02), non-alcoholic patients (18%, P<O.OOO 1) and normal controls (9%, P<O.OOO 1), but was similarly present in those in SAW group A (in abstinence for three months). Antibodies to horse ADH were also more prevalent in AAA patients compared to the SAW group B, non-alcoholic patients and healthy subjects. Moreover, reactivity to at least one form of ADH was more frequent in AAA than in SAW group B (P=O.0046), HBV infection (P=O.03), non-alcoholic patients (P<O.OOO 1) and healthy subjects (P<O.OOOI). Nine AAA patients were followed when they were into abstinence for a median of 40 days (range 30 to 100 days). Levels ofMCV, "YGT and IgA were lower during abstinence than at the time of drinking. In five AAA positive for antibodies to either form ofADH and studied during abstinence, the antibody levels decreased or became negative in 4 at days 40, 45, 90 and 100 into abstinence. Their demographic, clinical and immunological data are summarized in Table V .
Non-organ specific autoantibodies in patients with AAA
Non-organ specific autoantibodies were present in 12 of the 86 (14%) AAA patients: 8 had antismooth muscle antibodies (SMA) (titre range 1120 to 1180, median 1140), 2 anti-nuclear antibodies (ANA) (titre 1120), 1 anti-mitochondrial antibody (AMA) (titre 1/20) and 1 anti-liver kidney microsomal antibody type 1 (LKMI) (titre 1120). Three SAW patients (14%) were positive for nonorgan specific antibodies: 1 had ANA (titre 1/ 160),1 SMA (titre 1180)and 1 LKMI (titrel/160).
Inhibition ofADH enzymatic activity by sera positive for anti-ADH antibodies
Inhibition of ADH activity was investigated in 7 ALD patients, four being positive for anti-ADH [32 and horse ADH (titre 11300 to 111000) and three negative and in two normal controls. NADH generation was found to be linear with respect to time in tubes containing horse ADH only, sera from normal controls and ALD patients negative for anti ADH antibody. However, there was a lag phase in the time course up to 200 minutes of NADH production in the tubes containing sera from three ALD patients who were positive for anti-ADH antibodies (titre 11300 to 111000) ( Fig. 2) .
DISCUSSION
Our results show that approximately two thirds of patients actively abusing alcohol produce autoantibodies against alcohol dehydrogenase, the enzyme central to ethanol oxidation, with 64% of them being anti-ADH autoantibody positive compared to only 13% of patients on sustained alcohol withdrawal.
There is evidence that alcohol ingestion per se may be sufficient to trigger the production of autoantibodies (7) . Intragastrically alcohol fed rats produce autoantibodies to cytochrome P450 2El (CYP2EI), a major enzyme of the ethanol oxidising system, before the appearance of liver disease (23) .ln our own study, anti-ADH antibody prevalence was significantly lower in patients who had stopped drinking for more than 6 months than in those who did not stop drinking, indicating that alcohol withdrawal is accompanied by the disappearance of the autoantibody. This view was reinforced by the finding that three of four anti-ADH positive patients studied prospectively became anti-ADH seronegative after stopping drinking for a period ranging from 40 to 100 days. That these patients had effectively stopped drinking is indicated by the decrease in indices of the alcohol abuse such as MCV, ')'GT and IgA. Taken together, these data suggest that alcohol may indeed trigger anti-ADH autoantibody production directly.
The observation that anti-ADH antibodies were frequent in active alcohol abusers and closely related to alcohol consumption while non-organ specific antibodies such as ANA, SMA and LKM were relatively uncommon in the same patients, with a similar prevalence in alcohol abusers and in those on sustained alcohol withdrawal, further strengthens the link between abuse of alcohol and production of autoantibodies to the alcoholmetabolising ADH. Within the group of alcohol abusers, anti-ADH antibodies were more prevalent in patients with cirrhosis or with elevated levels of ALT than in those with steatosis or with normal levels of ALT. It is possible that a more severe liver disease and a higher prevalence of anti-ADH antibodies both reflect a higher alcohol intake. It is also possible that the ADH released from the cytoplasm ofdamaged hepatocytes acts as a stimulus to continuous autoantibody production. Relevantly, the highest prevalence of anti-ADH antibodies was found in patients with alcoholic hepatitis, a condition characterized by high levels of cytosolic liver enzymes circulating (7) .
Whether the humoral immune reaction to a key enzyme in ethanol metabolism such as ADH also contributes to the pathogenesis of alcoholic liver disease or is just a consequence of alcohol-induced liver damage remains to be established (13) . The fact that ADH autoantibodies can be found in some 10% of the normal controls would suggest that they are not influential in the development of alcoholic liver disease. On the other hand, the finding presented here that anti-ADH antibodies inhibit the activity of the native enzyme appears to indicate their pathogenic role, especially if the enzymatic inhibition observed in vitro also operates in vivo (24) . Antibodies to ADH delay NADH production, raising the possibility of a metabolic defect (Fig. 2 ). How this translates to an in vivo effect is still unclear. Prospective studies, investigating whether alcohol abusers with anti-ADH antibodies are at a greater risk ofliver damage than those anti-ADH antibody negative, are warranted and will give us an insight as to the pathogenic significance ofour observations and their relevance to hepatocyte destruction. An autoantibody induced inhibition of the ADH catalytic activity would favour ethanol metabolization through the CYP2El pathway or by gut bacteria ( 12) ; the free radicals generated in the first instance and endotoxin produced in the second are both capable of hepatocyte damage (12) . Against a pathogenic role for aIiti-ADH antibodies is the fact that their target is a cytosolic enzyme and, according to classical views, inaccessible to the effector molecules of the immune system. This notion has been challenged, however, by studies showing that antibodies directed to intracellular components, such as nuclear antigens, are capable of inflicting damage in vivo (25) (26) (27) (28) . Offurther relevance in understanding the pathogenic process is the fact that anti-ADH antibodies belong to the IgG isotype, implicating T-cell 'help' in their generation (29) (30) (31) (32) . This raises the possibility that ADH tolerance breakdown occurs not only at B cell level, but also T cell level, a possibility requiring future study.
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